Purpose: The prognostic significance of biomarkers in colorectal cancer is still being defined. This study aimed to determine the prognostic significance of BRAF mutation alone and in combination with microsatellite instability (MSI), in stage III colon cancer.
BRAF-mutated cancer patients do poorly. 4, 5 The presence of BRAF mutation in MSI CRC distinguishes sporadic MSI cases from Lynch syndrome, however, whether presence or absence of MSI has a prognostic impact on BRAF-mutated cancers is yet to be established. The aim of this study was to determine prognostic significance of both the BRAF mutation and the combination of BRAF/MSI in curatively resected stage III colon cancer.
METHOD
This was a retrospective cohort study, comparing survival in patients Statistical analyses were performed using the statistical software SAS 9.3 (SAS Institute Inc., Cary, NC). The primary study endpoint was cancer-specific survival. Noncancer deaths were censored. Associations among BRAF, MSI, and pathological factors were determined by logistic regression. Univariate analysis was performed using KaplanMeier survival curves and compared by the logrank test. Cox Regression proportional hazard models were used for multivariate analysis with backward elimination. Cancer-specific survival was compared among the groups MSI, BRAF, BRAF/MSI subgroups, and chemotherapy adjusted by various confounders. Four tumor categories were examined including: MSS and BRAF −ve (termed "traditional"), MSI and BRAF −ve (termed "presumed Lynch"), MSI and BRAF +ve (termed "sporadic MSI"), and MSS and BRAF +ve (termed "other BRAF"). The presence of a BRAF (V600E) mutation confirms sporadic MSI rather than germline 7,8 but we did not perform tests to identify the actual MMR mutation, these germline MSI cases are labelled as presumed Lynch. Backwards elimination was performed on each model to find a parsimonious model with all global P values < 0.1 (except for the BRAF/MSI variable, which was kept in the model).
RESULTS
Eight hundred and seventy-nine patients with stage III colon cancer were identified. Of these, 284 were excluded, 157 because insufficient On the multivariate model (Table 3, adjusting Adjusted analysis on the four subgroups showed that none were independently prognostically significant despite the univariate findings (Table 4) 
DISCUSSION
This was a retrospective cohort study investigating the impact of BRAF mutation (with and without MSI) on survival. BRAF mutation was associated with poorer survival when compared to BRAF wild type on univariate analysis. However, on multivariate analysis, there was no statistically significant relationship between BRAF and survival regardless of MSI status.
The BRAF V600E mutation occurs at a high frequency in serrated cancer and can helps distinguish inherited from sporadic cancers. 7, 8 Similar to previous reports, 4 we found that BRAF mutation was associated with some adverse features, such as poor differentiation, presence of mucin, extramural invasion, and high nodal stage, suggesting BRAF-mutated cancer should do poorly. However, when included in a multivariate analysis of stage III colon cancer patients only, we found that BRAF mutation was not an independent prognostic biomarker.
Previously published data have been conflicting. 5, 9, 10 A meta-analysis published in 2013 that included 26 CRC studies suggested that BRAF mutation is independently associated with poor survival. 4 However, We also investigated whether the combination of BRAF mutation and MSI status, might provide useful prognostic information beyond the evaluation of either factor alone. In concordance with previous studies, [11] [12] [13] the "other BRAF" group (BRAF +ve/MSS) with poor histo- (Table 4 ). The inability in our study to reach statistical significance, despite such a big difference in survival rates, may reflect with the low number of patients with this tumor phenotype. We did not observe the better outcome that some others have shown in Lynch patents. 2, 3 The current study has limitations. The incidence of BRAF mutation in our study was similar to that which is quoted in literature 14 but we found a slightly higher percentage of MSI and presumed
TA B L E 2 Comparing clinicopathologic characteristic between four subgroup patients
Lynch cases (8.4%), which likely reflects more comprehensive testing. ensure accuracy of data in our study, pathology was reassessed from slides on the earlier cases to meet current reporting protocols. Clinical information was also extensively crosschecked from different sources.
CONCLUSION
BRAF mutation was associated with poorer survival when compared to BRAF wild type on univariate analysis of stage III CRC. However, on multivariate-adjusted analysis there was no statistically significant relationship between BRAF and survival in stage III colon cancer regardless of MSI status.
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